Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Liabilities and Shareholders Equity: 2014-2025

Historic Liabilities and Shareholders Equity for vTv Therapeutics (VTVT) over the last 11 years, with Sep 2025 value amounting to $99.5 million.

  • vTv Therapeutics' Liabilities and Shareholders Equity rose 130.50% to $99.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 26.75%. This contributed to the annual value of $38.3 million for FY2024, which is 247.30% up from last year.
  • As of Q3 2025, vTv Therapeutics' Liabilities and Shareholders Equity stood at $99.5 million, which was up 276.19% from $26.4 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Liabilities and Shareholders Equity registered a high of $99.5 million during Q3 2025, and its lowest value of $11.0 million during Q4 2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $32.0 million (2025), whereas its average is $37.9 million.
  • In the last 5 years, vTv Therapeutics' Liabilities and Shareholders Equity surged by 346.13% in 2021 and then plummeted by 66.85% in 2023.
  • vTv Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $25.5 million in 2021, then soared by 30.48% to $33.2 million in 2022, then crashed by 66.85% to $11.0 million in 2023, then skyrocketed by 247.30% to $38.3 million in 2024, then spiked by 130.50% to $99.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $99.5 million for Q3 2025, versus $26.4 million for Q2 2025 and $32.0 million for Q1 2025.